Skip to main content

Schaeffer Orlov S Nicole's Form 4 filing

INSMED Inc (INSM) · filed Jan 10, 2025

Accession no.
0001628280-25-001205
Filed
Jan 10, 2025
Trade date
Jan 7-10, 2025
Filing delay
3 days
Rule 10b5-1 plan
Checked

This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $509.0K. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Schaeffer Orlov S NicoleCIK 0001401017Officer (Chief People Strategy Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 7, 2025Common StockSSaleDisposed−2,596$65.88F2−$171,024.4897,515Direct
Jan 8, 2025Common StockSSaleDisposed−1,209$65.84−$79,600.5696,306Direct
Jan 8, 2025Common StockAGrant or awardAcquired+5,706–F5–102,012Direct
Jan 10, 2025Common StockSSaleDisposed−965$63.87−$61,634.55101,047Direct
Jan 10, 2025Common StockSSaleDisposed−3,092$63.62−$196,713.0497,955Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 8, 2025Common StockAGrant or awardAcquired+27,370$0.00$027,370Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This is the weighted average sales price representing 2,596 shares sold at prices ranging from $65.72 to $65.96 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

Referenced by the price of 1 transaction in Table I.

F5

Each RSU was granted on January 8, 2025 for no consideration.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)